MarketPR
RBC Capital Markets has downgraded Biohaven, pointing to the company's recent deal with SK Biopharma as the catalyst for the call.
The move puts Biohaven in focus as the market weighs what the arrangement means for the near-term setup. The SK Biopharma transaction is what drove the action.
RBC's decision to step back on the rating signals that, in the firm's view, the partnership with SK Biopharma shifts the investment picture for Biohaven in a way that warranted a lower call.
Analyst downgrades from institutions of RBC's standing tend to prompt reassessment across the broader coverage community, and whether others following Biohaven arrive at the same conclusion on the SK Biopharma deal is the next read on the name.
Keep reading